Tumor Vaccine Therapy Against Advanced Gastric Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10
URLC10 has been identified as cancer specific molecules especially in non small cell lung
cancer using genome-wide expression profile analysis by cDNA microarray technique. In a
prior study, it has been shown that URLC10 are upregulated in esophageal cancer and gastric
cancer and other cancer. The investigators identified that peptides derived from these
proteins significantly induce the effective tumor specific CTL response in vitro. According
to these findings, in this trial, the investigators evaluate the safety, immunological and
clinical response of URLC10 peptide vaccine in the patients with gastric cancer. Patients
will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two
weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with
Montanide ISA 51 will be administered by endodermic injection
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety(Phase I:toxicities as assessed by NCI CTCAE version3)
28 days after beginning protocol
Yes
Hitoshi Shiozaki, MD
Study Chair
Department of Surgery
Japan: Institutional Review Board
20-27
NCT00845611
September 2008
September 2010
Name | Location |
---|